跳到正文
AACR 2026 现场信号· @ · X·· 2026-04-23评分60
正文 · 原文

Data from the phase 2 CANOPY trial showed promising activity and manageable safety with cabozantinib plus nivolumab in mCRPC. #AACR26 https://t.co/yS8ISSakid

热度 0 · 0 赞 · 0 回复 · 0 转发

会议摘要
3793按 药名 cabozantinib 对上
Preventing nk cell activation in the damaged liver induced by cabozantinib/pd-1 blockade increases survival in hepatocellular carcinoma models

Satoru Morita, Tomofumi Ando, Hiroto Kikuchi, Atsuyo Morita, Tatsuya Kobayashi, Grace Birch, Ryota Tanaka, Aya Matsui, Zhiping Ruan, Peigen Huang, Alexei Hernandez, Erin M. Coyne, Sarah M. Shin, Robin Kate Kelley, Mark Yarchoan, Stefan Halvorsen, Slim Sassi, Mari Mino Kenudson, Shadmehr Demehri, Rizwan Romee, Won Jin Ho, Dan Duda

读摘要原文 →

来源:AACR 2026 现场信号 · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org